TACROLIMUS

1. Product introduction

　　Tacrolimus (acrolimus), also known as FK506, is a fermentation product isolated from Streptomyces tsukubaensis, whose chemical structure belongs to the 23-member macrolide antibiotic. It is a powerful new type of immunosuppressant, mainly by inhibiting the release of interleukin-2 (L-2) to fully inhibit the role of T lymphocytes, 100 times stronger than cyclosporine (CsA). In recent years, as a first-line drug for liver and kidney transplantation, it has been marketed in 14 countries, including Japan and the United States. Clinical experiments have shown that its application in heart, lung, intestinal and bone marrow transplantation has good efficacy. Meanwhile, FK506 also plays an active role in the treatment of autoimmune diseases such as atopic dermatitis (AD), systemic lupus erythematosus (SLE), and autoimmune ophthalmopathy.

2. Technology 

　　Final titre: 2-3g/L; 
　　Fermentation time:14 days; 
　　Recovery yield: >60%